Holen Sie sich die Stockscreener-App
8.32
1.65%
-0.14
Handel nachbörslich:
8.40
0.08
+0.96%
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Number of shareholders of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
ORIC: Oric PharmaceuticalsInteractive Chart - Zacks Investment Research
Wall Street Zen Downgrades Oric Pharmaceuticals (NASDAQ:ORIC) to Strong Sell - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A 135.75% Potential Upside for Investors in the Biotech Sector - DirectorsTalk Interviews
Q2 EPS Estimate for Oric Pharmaceuticals Lowered by Analyst - MarketBeat
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $15 to $25 - Moomoo
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat
ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart
MSN Money - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - The Manila Times
ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan
Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan
BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView
Oric Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ... - Bluefield Daily Telegraph
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) 2026 proxy details equity plan changes, director elections, auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmace - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Investors to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) to Release Earnings on Monday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceutical - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):